X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse ASTRAZENECA PHARMA with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs MYLAN (US) - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ASTRAZENECA PHARMA   MYLAN
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
MYLAN
Dec-18
ASTRAZENECA PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,2783,263-   
Low Rs8831,796-   
Sales per share (Unadj.) Rs228.41,501.7-  
Earnings per share (Unadj.) Rs10.440.8-  
Cash flow per share (Unadj.) Rs16.3321.9-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs98.81,624.5-  
Shares outstanding (eoy) m25.00514.50-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.71.7 280.8%   
Avg P/E ratio x104.262.0 168.0%  
P/CF ratio (eoy) x66.47.9 845.5%  
Price / Book Value ratio x10.91.6 702.3%  
Dividend payout %00-   
Avg Mkt Cap Rs m27,0081,301,615 2.1%   
No. of employees `0001.435.0 3.9%   
Total wages/salary Rs m1,5350-   
Avg. sales/employee Rs Th4,210.922,074.4 19.1%   
Avg. wages/employee Rs Th1,132.20-   
Avg. net profit/employee Rs Th191.1599.4 31.9%   
INCOME DATA
Net Sales Rs m5,710772,603 0.7%  
Other income Rs m1230-   
Total revenues Rs m5,833772,603 0.8%   
Gross profit Rs m463199,921 0.2%  
Depreciation Rs m147144,662 0.1%   
Interest Rs m037,160 0.0%   
Profit before tax Rs m43818,100 2.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m179-2,880 -6.2%   
Profit after tax Rs m25920,979 1.2%  
Gross profit margin %8.125.9 31.3%  
Effective tax rate %40.8-15.9 -256.7%   
Net profit margin %4.52.7 167.1%  
BALANCE SHEET DATA
Current assets Rs m3,209431,421 0.7%   
Current liabilities Rs m2,070314,553 0.7%   
Net working cap to sales %20.015.1 132.0%  
Current ratio x1.61.4 113.1%  
Inventory Days Days7284 86.6%  
Debtors Days Days3593 37.4%  
Net fixed assets Rs m790149,872 0.5%   
Share capital Rs m50411 12.2%   
"Free" reserves Rs m2,4190-   
Net worth Rs m2,469835,815 0.3%   
Long term debt Rs m0902,112 0.0%   
Total assets Rs m4,6052,241,981 0.2%  
Interest coverage xNM1.5-  
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x1.20.3 359.8%   
Return on assets %5.62.6 217.0%  
Return on equity %10.52.5 418.0%  
Return on capital %17.73.2 557.9%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-1,7150-   
CASH FLOW
From Operations Rs m88160,547 0.1%  
From Investments Rs m-94-82,985 0.1%  
From Financial Activity Rs mNA-74,792 0.0%  
Net Cashflow Rs m-61,330 -0.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 68.56 Rs / USD

Compare ASTRAZENECA PHARMA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare ASTRAZENECA PHARMA With: ALEMBIC LTD  TTK HEALTHCARE  STRIDES PHARMA SCIENCE  WOCKHARDT  CIPLA  



Today's Market

Sensex Ends 234 Points Higher; Healthcare and Realty Stocks Rally(Closing)

After opening the day on a flat note, Indian share markets witnessed buying interest during closing hours and ended higher.

Related Views On News

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

I Believe this is the Best Stock to Buy Today (Profit Hunter)

Jul 3, 2019

The languishing small cap space is currently offering a very fertile market to pick up bargains at very attractive prices. This is a perfect opportunity ripe for the picking.

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound (Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On... (The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors (The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance (The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jul 16, 2019 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS